Year: 2017
Type: article
Abstract: T cell therapies have shown promise against viral infections and malignancies. Moreover, advances in gene-editing technology hold the promise that T cell potency can be enhanced by gene modification, deletion, or addition.1 In this issue of Molecular Therapy, Hale et al.,2 in a single construct, combine CCR5 knockdown with a chimeric antigen receptor targeting the HIV envelope, a combination strategy that can potentially provide both anti-HIV activity independent of major histocompatibility complex (MHC) expression and protection of gene-modified T cells from HIV infection.
Source: Molecular Therapy
Authors: Conrad Russell Cruz, Catherine M. Bollard
Institutions: Children's National, George Washington University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2586826486